Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up.

doi:10.1016/j.leukres.2012.07.019

Article

Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up.

Leukemia research - 1 Nov 2012

Matsuda Kazuyuki, Ishida Fumihiro, Ito Toshiro, Nakazawa Hideyuki, Miura Shuhei, Taira Chiaki, Sueki Akane, Kobayashi Yukihiro, Honda Takayuki

Abstract excerpt

Various gene mutations have been reported in patients with myelodysplastic syndrome (MDS). Serial studies of mutations during follow-up are important for investigating the stability of the mutations for use as minimal residual disease (MRD) markers. Sequential quantitative analyses of 5 patients with spliceosome-related gene mutations by allele-specific quantitative polymerase chain reaction revealed that the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up.

Abstract excerpt

Topics

Related research